AC Immune Stock Price, News & Analysis

AC Immune reported its 2022 financial results showcasing a cash position of CHF 122.6 million, providing runway into Q3 2024. The company recorded CHF 3.9 million in contract revenues, a significant increase from zero in the prior year. R&D expenditures decreased to CHF 60.3 million, primarily due to advancements in clinical studies for ACI-24.060. The net loss was CHF 70.8 million, a slight improvement from CHF 73.0 million in 2021. Looking ahead, the company anticipates a cash burn of CHF 65 to CHF 75 million for 2023, and milestones for its anti-amyloid and anti-Tau vaccine developments are set for 2023.

AC Immune (NASDAQ: ACIU) has announced a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023, at 7:00 am ET. After the announcement, management will be available for one-on-one calls with investors and analysts to discuss the results and outlook for 2023. The company focuses on precision medicine for neurodegenerative diseases, utilizing its two technology platforms, SupraAntigen® and Morphomer®, and has a robust pipeline with ten therapeutic and three diagnostic candidates.

AC Immune has secured significant funding through grants from The Michael J. Fox Foundation and Target ALS Foundation totaling over USD 500,000. The grants will support the development of a first-in-class TDP-43 PET tracer and innovative biofluid assays for TDP-43-related neuropathology, crucial in neurodegenerative diseases like ALS and FTLD. The MJFF grant aims to facilitate the creation of the first imaging agent for TDP-43, while the Target ALS grant promotes collaboration among major institutions to enhance diagnostic capabilities. These initiatives align with AC Immune's precision medicine strategy to revolutionize early diagnosis and treatment in the neurodegenerative disease sector.

AC Immune will participate in the SVB Securities Global Biopharma Conference from February 14-16, 2023. Management will engage in a fireside chat on February 14 at 8:40 AM ET / 2:40 PM CET, where CEO Dr. Andrea Pfeifer will outline the company's precision medicine approach and pipeline, which includes 16 therapeutic and diagnostic programs. Notably, the ACI-24.060 vaccine has shown positive results in initial trials for Alzheimer’s disease. A replay of the presentation will be available on AC Immune’s events page after the live event.

AC Immune announced positive interim findings from the Phase 1b/2 ABATE trial of its anti-amyloid-beta vaccine ACI-24.060 for Alzheimer’s disease. The vaccine showed an anti-Abeta antibody response in the first low-dose cohort and was generally well tolerated, with no safety concerns. Dosing in the second higher dose cohort has commenced, and screening for a cohort with Down syndrome is also approved. Preliminary safety and immunogenicity data are expected in H2 2023, with initial PET imaging results on plaque reduction anticipated in 2024. These results may position ACI-24.060 as a promising therapeutic option for AD.

AC Immune has announced the initiation of the Phase 3 ADvance study involving PI-2620, a Tau PET diagnostic agent for Alzheimer’s disease. This trial, conducted in collaboration with Life Molecular Imaging, aims to assess the safety and diagnostic accuracy of PI-2620 in detecting Tau pathology, a critical factor in Alzheimer’s progression. The first patient has already been imaged, marking a significant milestone. PI-2620 is recognized for its high binding affinity and potential as a best-in-class Tau tracer. Successful results may lead to market approval, furthering advancements in Alzheimer’s diagnostics.

AC Immune announced that its Alzheimer’s vaccine candidate ACI-35.030 has been selected for further development following positive interim data from a Phase 1b/2a trial. The vaccine demonstrated excellent clinical performance, inducing specific antibodies against pathological Tau, a key player in Alzheimer’s disease. This selection marks significant progress in AC Immune’s collaboration with Janssen Pharmaceuticals. The company now advances three vaccine candidates in Phase 2 trials, reinforcing its position in neurodegenerative disease treatment.

AC Immune SA (NASDAQ: ACIU) has announced the presentation of its innovative SupraAntigen® liposomal vaccine platform at the upcoming CTAD conference in San Francisco from November 29 to December 2, 2022. The company will present data on its anti-phospho-Tau vaccines, ACI-35 and JACI-35, showcasing their safety and immunogenicity. Key presentations include interim data from a Phase 1b/2a study and insights into biomarkers related to Alzheimer’s disease. This highlights AC Immune's commitment to developing targeted active vaccines for neurodegenerative diseases.

AC Immune SA (NASDAQ: ACIU), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the 2022 Jefferies London Healthcare Conference from November 15-17, 2022. CEO Dr. Andrea Pfeifer will discuss the company's precision medicine approach and its pipeline, aiming for earlier diagnosis and prevention of diseases like Alzheimer’s. Notably, an interim analysis of the Phase 1b/2 ABATE study on the anti-amyloid-beta vaccine ACI-24.060 is among three key clinical readouts expected by year-end. The fireside chat is set for November 15, 2022, at 3:00 AM ET.